Richard Schlenk

22PUBLICATIONS
163CO-AUTHORS
Immunogenetics (incl. genetic immunology)Molecular targetsQuantum optics and quantum optomechanicsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 01, 2026
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

|Apr 09, 2026
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor.

Marcus Renner, Małgorzata Oleś, Nagarajan Paramasivam

|Apr 08, 2026
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Oct 06, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Mark J Levis, Harry P Erba, Pau Montesinos

|Sep 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Frank G Rücker, Lars Bullinger, Sibylle Cocciardi

|Sep 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.

Julia M Unglaub, Richard F Schlenk, Jan Moritz Middeke

Pageof 4

Frequent Collaborators

5 joint publications

Carsten Müller-Tidow

4 joint publications

Maria Teresa Voso

3 joint publications

Helmut Salih

3 joint publications

Richard Larson